Capricorn Pharma and Teva Pharmaceuticals USA Ink Product Development Pact.
HEALTH AND BEAUTY CLOSE-UP-8 August 2008-Capricorn Pharma and Teva Pharmaceuticals USA Ink Product Development Pact(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com S. Rao Cherukuri, Founder, President and CEO of Capricorn Pharma, announced that his company has an agreement with Teva Pharmaceuticals USA to develop products using Capricorn's proprietary Korkoat...

OREXO PATENT FOR RAPID DELIVERY ISSUED IN EU.
Orexo Pharmaceuticals has announced that a European Patent has been granted for one of their technology platforms, the sublingual tablet technology. Several of the company's product projects are based on this technology. The technology enables rapid absorption of pharmaceutical compounds and can in certain cases substitute for injections. ...

Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China.
HEALTH AND BEAUTY CLOSE-UP-17 January 2007-Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China(C)2007 - CloseUpMedia - newsdesk@closeupmedia.com Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, reported that...

Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China.
- Launch Represents First Market Introduction of a Therapeutic Based on Peregrine's TNT Anti-Cancer Technology - TUSTIN, Calif., Jan. 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today reported...

Duramed Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2000 Results; Comments on Pipeline and 2001 Outlook.
- Hormone sales lead company's return to profitability for the year CINCINNATI, Feb. 28 /PRNewswire/ -- Duramed Pharmaceuticals, Inc. (Nasdaq: DRMD) announced today its results for the fourth quarter and fiscal year ended December 31, 2000. For the fourth quarter 2000, net sales were $23.8...

Jazz Pharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results.
XYREM(R) Sales Reach Record $14.2 Million Reductions Implemented in Commercial Organization PALO ALTO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. today announced financial results for the quarter ended September 30, 2008. Product revenues for the quarter ended September 30, 2008 were $17.0...

Palatin Technologies, Inc. Reports Fiscal Year 2007 First Quarter Results; Conference Call and Webcast Being Held Today at 10:00 a.m. EST.
CRANBURY, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. announced today financial results for the first quarter ended September 30, 2006. Total revenues in the quarter were $4.9 million, compared to $5.1 million for the same period in 2005. Palatin reported a net loss of $8.4 million, or ($0.12)...

Access Pharmaceuticals Provides an Update on Advances In Its Cobalamin(TM) Oral Drug Delivery Product Development.
Data demonstrates that new Cobalamin oral insulin and oral human growth hormone formulations provide significant pharmacological responses in preclinical models DALLAS, Jan. 14 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) provided an update today on its Cobalamin(TM) oral drug delivery product development programs. The proprietary Cobalamin(TM)...

Catalyst Biosciences Raises $40 Million in Series C Financing.
SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, has raised $40.4 million in a Series C financing round. New investor Essex Woodlands Health Ventures led the round, with participation from existing investors...

Alexza Pharmaceuticals and Symphony Capital Enter into $50 Million Product Development Collaboration for AZ-002 and AZ-004.
Alexza Holds Conference Call at 9:00 a.m. E.T. to Discuss Collaboration PALO ALTO, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that it has completed a transaction with Symphony Capital Partners, LP and its co-investors to provide $50 million to fund the development of AZ-002...